Adjuvant denosumab for early breast cancer-Evidence and controversy

Breast. 2024 Dec:78:103826. doi: 10.1016/j.breast.2024.103826. Epub 2024 Oct 23.

Abstract

The efficacy of adjuvant denosumab in combination with hormonotherapy in breast cancer patients was investigated in two randomized trials, ABCSG-18 and D-Care, but the results were mixed with respect to the impact of this drug on disease-free survival. However, the ABCSG-18 study has achieved its primary goal: prevention of clinical fractures. Therefore, the protective role of Denosumab on bone fragility induced by estrogen deprivation, already demonstrated in post-menopausal women, has been validated in the breast cancer setting.

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / adverse effects
  • Bone Density Conservation Agents* / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / metabolism
  • Breast Neoplasms* / mortality
  • Chemotherapy, Adjuvant
  • Denosumab* / therapeutic use
  • Disease-Free Survival
  • Female
  • Fractures, Bone / chemically induced
  • Fractures, Bone / metabolism
  • Fractures, Bone / prevention & control
  • Humans
  • Randomized Controlled Trials as Topic

Substances

  • Antineoplastic Agents, Hormonal
  • Bone Density Conservation Agents
  • Denosumab